Lacosamid Zentiva (Lacosamide)

Lacosamide is an anticonvulsant that acts on neuronal sodium channels to control seizure activity.

• Partial‑onset seizures: reduces seizure frequency when added to existing therapy.
• Primary generalized tonic‑clonic seizures: provides adjunctive seizure control in combination with other antiepileptics.

• Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing hyper‑excitable neuronal membranes and limiting repetitive firing. The drug binds to the intracellular domain of the channel, shifting the equilibrium toward the inactivated state. This action diminishes the ability of neurons to fire high‑frequency action potentials that underlie epileptic discharges, providing therapeutic benefit in focal and generalized seizure types.

Lacosamide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Dizziness: sensation of light‑headedness or imbalance.
• Nausea: mild to moderate stomach upset.
• Headache: intermittent or persistent pain.
• Fatigue: feeling unusually tired.
• Diplopia: double vision.
• Tremor: mild shaking of limbs.

Serious or Rare Side Effects

• Cardiac arrhythmia: irregular heart rhythm, including PR interval prolongation.
• Suicidal thoughts: emergence of depressive symptoms or suicidal ideation.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Respiratory depression: difficulty breathing in severe cases.

When prescribing Lacosamid Zentiva, clinicians should consider several safety measures.

• Cardiac monitoring: assess ECG for PR interval prolongation, especially in patients with cardiac disease.
• Renal impairment: adjust dose in patients with severe renal dysfunction.
• Hepatic impairment: use caution and consider dose reduction in liver disease.
• Pregnancy: avoid use unless benefits outweigh potential risks, as safety data are limited.
• Discontinuation: do not stop abruptly; taper to reduce seizure recurrence risk.
• Store at below 25°C: keep in original packaging, protect from moisture and light.

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers: may reduce lacosamide plasma levels, decreasing effectiveness.
• Concomitant sodium channel blockers (e.g., carbamazepine, phenytoin): increase risk of cardiac conduction abnormalities.
• Dual antiplatelet therapy: heightened bleeding risk when combined with anticoagulants.

Moderate Interactions (Monitor Closely)

• Hormonal contraceptives: may lower contraceptive efficacy, requiring additional methods.
• Antidepressants (e.g., SSRIs): monitor for increased risk of suicidal thoughts.
• Diuretics: watch for electrolyte disturbances that could affect cardiac rhythm.